383 related articles for article (PubMed ID: 33763071)
41. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
42. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas.
Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C
Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751
[TBL] [Abstract][Full Text] [Related]
43. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
44. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
45. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
46. TLS in Tumors: What Lies Within.
Sautès-Fridman C; Fridman WH
Trends Immunol; 2016 Jan; 37(1):1-2. PubMed ID: 26706045
[TBL] [Abstract][Full Text] [Related]
47. Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking.
Jackutė J; Žemaitis M; Pranys D; Šitkauskienė B; Miliauskas S; Bajoriūnas V; Sakalauskas R
Medicina (Kaunas); 2015 Nov; 51(5):263-71. PubMed ID: 26674143
[TBL] [Abstract][Full Text] [Related]
48. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.
Chae YK; Choi WM; Bae WH; Anker J; Davis AA; Agte S; Iams WT; Cruz M; Matsangou M; Giles FJ
Sci Rep; 2018 Jan; 8(1):1023. PubMed ID: 29348685
[TBL] [Abstract][Full Text] [Related]
51. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
[TBL] [Abstract][Full Text] [Related]
52. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
Seow DYB; Yeong JPS; Lim JX; Chia N; Lim JCT; Ong CCH; Tan PH; Iqbal J
Breast Cancer Res Treat; 2020 Apr; 180(2):369-377. PubMed ID: 32034580
[TBL] [Abstract][Full Text] [Related]
53. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
Dieu-Nosjean MC; Antoine M; Danel C; Heudes D; Wislez M; Poulot V; Rabbe N; Laurans L; Tartour E; de Chaisemartin L; Lebecque S; Fridman WH; Cadranel J
J Clin Oncol; 2008 Sep; 26(27):4410-7. PubMed ID: 18802153
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
55. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
[TBL] [Abstract][Full Text] [Related]
56. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
Xiaoxu D; Min X; Chengcheng C
BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
[TBL] [Abstract][Full Text] [Related]
57. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
[TBL] [Abstract][Full Text] [Related]
58. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
59. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
60. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
